Ondine Biomedical Inc Common Share (OBI)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
10.00p
Buy
10.50p
0.00p (+0.00%)
Prices updated at 12 Dec 2025, 17:08 GMT
| Prices minimum 15 mins delay
Prices in GBX
Ondine Biomedical Inc. is dedicated to the development of non-antibiotic anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Jean Charest
CEO
Ms. Carolyn Cross
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
8,000
Head office
1100 Melville Street
Vancouver
Canada
V6E4A6
Key personnel
Owner name | Salary |
|---|---|
Ms. Jean Duvall Non-Executive Director, Senior Independent Non-Executive Director | - |
Mr. Jean Charest Non-Executive Director, Chairman | - |
Ms. Margaret Shaw Non-Executive Director | - |
Dr. Junaid Bajwa Non-Executive Director | - |
Ms. Carolyn Cross Executive Director, Chief Executive Officer | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Janus Henderson Investors Ltd | 50,043,503 |
| Law Debenture Corporation | 50,043,503 |
| M&G Investment Management Limited | 40,588,235 |
| M&G Recovery Fund | 40,588,235 |
| Chelverton Asset Management Ltd | 18,551,874 |
Director dealings
Date | Action |
|---|---|
| 03 Sep 2025 | Purchase |
| 03 Sep 2025 | Purchase |
| 03 Sep 2025 | Purchase |
| 03 Sep 2025 | Purchase |
| 28 Aug 2025 | Purchase |
| 05 Feb 2025 | Purchase |
| 03 Feb 2025 | Purchase |
| 31 Jan 2025 | Purchase |
| 30 Jan 2025 | Purchase |
| 29 Jan 2025 | Purchase |
Please note that past performance is not a reliable indicator of future returns.
